Inclusion Criteria
Concurrent Medication:
Allowed:
- Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study entry.
- Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF on a stable prophylactic regimen for at least 4 weeks prior to study entry.
Patients must have:
- HIV seropositivity.
- Elevated p24 antigen (> 40 pg/ml).
- Mean CD4 count <= 100 cells/mm3.
- Life expectancy of at least 3 months.
Prior Medication:
Allowed:
- Other prior antiretroviral therapy.
- Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms or conditions are excluded:
- Inadequate venous access.
- Active serious infection (other than HIV infection) requiring parenteral antibiotic therapy.
- Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
- Psychiatric disturbance or illness that may affect compliance.
- Malignancy other than Kaposi's sarcoma.
Concurrent Medication:
Excluded:
- Investigational agents other than stavudine (d4T).
- Interferon-alpha.
- Ganciclovir.
- Foscarnet.
- Diuretics.
- Amphotericin B.
- Aminoglycoside antibiotics.
- Other nephrotoxic agents.
- Acyclovir at doses >= 2 g/day.
Prior Medication:
Excluded within 2 weeks prior to study entry:
- Investigational agents other than stavudine (d4T).
- Interferon-alpha.
- Ganciclovir.
- Foscarnet.
- Diuretics.
- Amphotericin B.
- Aminoglycoside antibiotics.
- Other nephrotoxic agents.
Excluded within 4 weeks prior to study entry:
- Systemic therapy for Kaposi's sarcoma. Substance abuse.
Purpose
